September 19, 2024: MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update
MaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update [fancy-ul icon_type="standard_dash" color="Accent-Color" alignment="left" spacing="default"] Positive efficacy and safety data of MaaT013 in aGvHD in the Early Access Program presented at the EBMT 2024 annual meeting with 63% GI-ORR at D28, a 49% one year and 42% 18 months Overall Survival [...] 